[LONDON] A 25 per cent US tariff on pharmaceutical imports would increase US drug costs by nearly US$51 billion annually, boosting US prices by as much as 12.9 per cent if passed on, a report commissioned by the industry’s US trade group and reviewed by Reuters shows.
The analysis, conducted by Ernst & Young, found the US imported US$203 billion in pharmaceutical products in 2023, with 73 per cent coming from Europe – primarily Ireland, Germany and Switzerland. Total US sales of finished pharmaceuticals that year were US$393 billion.
The report, dated Apr 22 and not made public, was commissioned by the main US pharmaceutical lobby, the Pharmaceutical Research and Manufacturers of America, whose members include Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, among others.
PhRMA did not immediately respond to a request for comment. The group has argued tariffs would undermine efforts to boost domestic manufacturing, a goal of US President Donald Trump.
Pharmaceutical products have long been spared from trade wars due to the potential harms, but he has repeatedly threatened a 25 per cent tariff on pharmaceutical imports.
Last week, the Trump administration announced probes into pharmaceutical imports, citing national security concerns over reliance on foreign drug production.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
The move triggered a 21-day public comment period as part of the investigation led by the Commerce Department.
Drugmakers see the probe as a chance to show the administration that high tariffs would hinder their efforts to swiftly ramp up US production, and to propose alternatives, said Ted Murphy, a trade lawyer at law firm Sidley Austin, which is advising companies on their submissions to the Commerce Department.
Drugmakers have also lobbied Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the charges.
On Thursday (Apr 24), Swiss drugmaker Roche said it is petitioning the US government in direct talks for import tariff exemptions, arguing the products it ships into the US are offset by its exports of US-made drugs and diagnostics.
Production costs are only one factor shaping the price of newer medicines and it is unclear to what extent tariffs on imported intermediate inputs or imported finished products would be passed forward to consumers, the report said.
Tariffs on imported finished products could be passed through to consumers by the wholesale or retail distributors paying the tariff.
But if duties were fully passed on through higher prices on domestic sales, EY estimates US drug prices could rise up to 12.9 per cent.
Approximately 30 per cent of pharmaceutical imports in 2023 were ingredients used in US manufacturing and then exported or sold in the US.
Tariffs on these would raise domestic production costs by 4.1 per cent and reduce the global competitiveness of US-made drugs, the report said.
Roughly 25 per cent of US pharmaceutical output is exported, which totalled US$101 billion in 2023. EY said a portion of the 490,000 export-related jobs in the industry could be at risk if higher input costs weaken foreign demand for US medicines.
The report did not include the impact of possible retaliatory tariffs. The economic impact of those for US producers would be much more significant. REUTERS
